Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (1111)	11/12/2001 9:33:03 PM
From: Arthur Radley	Respond to of 1475

part 2 by: soldier30 11/12/01 09:05 pm Msg: 1301 of 1302 ú Abstracts from the upcoming ASH meeting show encouraging data from studies with AlloMune; BTRN's partner, Gambro BCT, will be sponsoring a symposium at ASH. The abstracts from the upcoming American Society of Hematology (ASH) meeting were released earlier this week. Two studies involving the AlloMune system for cancer have shown some encouraging early results. The first evaluated the impact of donor lymphocyte infusions in 46 patients with advanced hematologic malignancies treated with the AlloMune protocol. In bone marrow transplant for refractory blood cancers, donor lymphocyte infusion (DLI) is a technique to boost the white blood cells of the recipient to potentially increase the response rate. In this study, 18 patients received DLI and 50% (9/18) had a complete response. In the patients who did not receive DLI, 25% (7/28) had a complete response. A second abstract details the durable responses in another 19 refractory aggressive lymphoma patients treated with the AlloMune protocol (which includes MEDI-507). Forty-two percent (8/19) of patients achieved either a complete response (5/19, 26%) or a partial response (3/19, 16%). Five (26%) of these patients are still alive and progression free at 13 - 52 months post-transplant. We are particularly encouraged by the high level of response rates in those patients receiving DLI and the durability of these responses. BioTransplant's marketing partner for the Eligix cell separation devices, Gambro BCT, will sponsor a symposium to discuss cell separation and its role in enhancing patient outcomes through graft engineering on Sunday, December 9, 2001, at 6 p.m. at the Rosen Plaza Hotel in Orlando.